Evidence map›Paper›PMID 36335224›Full record

ArticleScientific reports2022

Predicting overall survival in diffuse glioma from the presurgical connectome.

Shelli R Kesler, Rebecca A Harrison, Vikram Rao, Hannah Dyson, Melissa Petersen, Sarah Prinsloo

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Shelli R KeslerDepartment of Adult Health, School of Nursing, University of Texas at Austin, 1710 Red River St, Austin, TX, D010078712, USA. srkesler@austin.utexas.edu.
Rebecca A HarrisonDivision of Neurology, University of British Columbia, Vancouver, BC, Canada.
Vikram RaoDepartment of Adult Health, School of Nursing, University of Texas at Austin, 1710 Red River St, Austin, TX, D010078712, USA.
Hannah DysonDepartment of Internal Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA.
Melissa PetersenDepartment of Family Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA.
Sarah PrinslooDepartment of Neurosurgery, MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas at Austin · USThe University of Texas MD Anderson Cancer Center · USUniversity of British Columbia · CAUniversity of North Texas · USUniversity of North Texas Health Science Center · US

Funding

Very-long Term Neurocognitive Outcomes in Breast Cancer Survivors (ProbC2)R01CA172145 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI KESLER, SHELLI R, PALESH, OXANA G · 2012 to 2024
$3.3M
Using Connectomics and Machine Learning to Predict Survival in Diffuse GliomaR03CA241862 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI KESLER, SHELLI R · 2021 to 2022
$174k
NCI NIH HHS R01 CA172145NCI NIH HHS R03 CA241862
6 · The paper itself

Abstract

Diffuse gliomas are incurable brain tumors, yet there is significant heterogeneity in patient survival. Advanced computational techniques such as radiomics show potential for presurgical prediction of survival and other outcomes from neuroimaging. However, these techniques ignore non-lesioned brain features that could be essential for improving prediction accuracy. Gray matter covariance network (connectome) features were retrospectively identified from the T1-weighted MRIs of 305 adult patients diagnosed with diffuse glioma. These features were entered into a Cox proportional hazards model to predict overall survival with 10-folds cross-validation. The mean time-dependent area under the curve (AUC) of the connectome model was compared with the mean AUCs of clinical and radiomic models using a pairwise t-test with Bonferroni correction. One clinical model included only features that are known presurgery (clinical) and another included an advantaged set of features that are not typically known presurgery (clinical +). The median survival time for all patients was 134.2 months. The connectome model (AUC 0.88 ± 0.01) demonstrated superior performance (P < 0.001, corrected) compared to the clinical (AUC 0.61 ± 0.02), clinical + (AUC 0.79 ± 0.01) and radiomic models (AUC 0.75 ± 0.02). These findings indicate that the connectome is a feasible and reliable early biomarker for predicting survival in patients with diffuse glioma. Connectome and other whole-brain models could be valuable tools for precision medicine by informing patient risk stratification and treatment decision-making.

Indexed as

Brain NeoplasmsConnectomeGliomaAdultHumansMagnetic Resonance ImagingRetrospective Studies

Identifiers

PMID36335224
PMCPMC9637134
OpenAlexW4308262990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.